The journal papers in the table in previous post (and included in here), are the ones I use to argue ALS median is ordinarily slightly below three years for symptom onset.

Table of ALS datasets

bump . . . so the is easy to find due to historical information and

includes reference to the growing national database . . . :

CDC – National Amyotrophic Lateral Sclerosis (ALS) Registry

At least two of the studies in the list might have median life expectancy above 51 months, Taiwan's 1149 and Scandinavia's 155 (72). Eleven others remain undiscovered.

(this post is intended for a different thread but I left it here also).

Further to the immediately preceding post . . . the original Phase II study's median was 56 months (n=84), about five months more than RespiTrimALS 51 months (n=37) in their treatment group. I am not sure I understand their specification for the non-stimulation group - it seems to be more then ten years. I just discovered the Scandinavia study (n=155) was of PMA patients rather than ALS patients, 72 months. Taiwan's was 66.6 months for (n=1149) where 241 patients were on a tracheostomy.

Protocol for diaphragm pacing in patients with respiratory muscle weakness due to motor neurone disease (DiPALS): a randomised controlled trial | BMC Neurology | Full Text

Here again is an URL for crude table of studies . . . (n= ) follows the author's name in each row and the next number to the right is survival (either median or average). Although some are unknown, most are 36 months or less:

Table of ALS datasets

Hence, superficially, RespiTrimALS results appear significantly better than normal.